These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30022307)

  • 1. Costs of Managing Benign Prostatic Hyperplasia in the Office and Operating Room.
    Gill BC; Ulchaker JC
    Curr Urol Rep; 2018 Jul; 19(9):72. PubMed ID: 30022307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Comparison of Benign Prostatic Hyperplasia Treatment Options.
    DeWitt-Foy ME; Gill BC; Ulchaker JC
    Curr Urol Rep; 2019 Jun; 20(8):45. PubMed ID: 31218458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urologic diseases in America project: benign prostatic hyperplasia.
    Wei JT; Calhoun E; Jacobsen SJ
    J Urol; 2005 Apr; 173(4):1256-61. PubMed ID: 15758764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of benign prostatic hyperplasia.
    Pinheiro LC; Martins Pisco J
    Tech Vasc Interv Radiol; 2012 Dec; 15(4):256-60. PubMed ID: 23244720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BPH: costs and treatment outcomes.
    Nickel JC
    Am J Manag Care; 2006 Apr; 12(5 Suppl):S141-8. PubMed ID: 16613528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options.
    Liatsikos E; Kyriazis I; Kallidonis P; Stolzenburg JU
    Aging Male; 2011 Sep; 14(3):141-9. PubMed ID: 21247241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
    Plosker GL; Goa KL
    Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II--results.
    Blute M; Ackerman SJ; Rein AL; Beusterien K; Sullivan EM; Tanio CP; Strauss MJ; Manyak MJ
    Urology; 2000 Dec; 56(6):981-7. PubMed ID: 11113744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign prostatic hyperplasia. Practical treatment guidelines.
    Tammela T
    Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies.
    Yu X; Elliott SP; Wilt TJ; McBean AM
    J Urol; 2008 Jul; 180(1):241-5; discussion 245. PubMed ID: 18499180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
    Walker A; Doyle S; Posnett J; Hunjan M
    BJU Int; 2013 Sep; 112(5):638-46. PubMed ID: 23356792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical therapy versus surgery and minimally invasive surgical therapies for lower urinary tract symptoms and benign prostatic hyperplasia: what makes better economic sense?
    Stovsky MD; Rhee K; Hartke D
    Curr Urol Rep; 2007 Jul; 8(4):289-97. PubMed ID: 18519013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benign prostatic hyperplasia: current clinical practice.
    Djavan B; Eckersberger E; Finkelstein J; Espinosa G; Sadri H; Brandner R; Shah O; Lepor H
    Prim Care; 2010 Sep; 37(3):583-97, ix. PubMed ID: 20705200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy.
    Manyak MJ; Ackerman SJ; Blute ML; Rein AL; Buesterien K; Sullivan EM; Tanio CP; Strauss MJ
    J Endourol; 2002 Feb; 16(1):51-6. PubMed ID: 11890452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BPH update: medical versus interventional management.
    Blankstein U; Van Asseldonk B; Elterman DS
    Can J Urol; 2016 Feb; 23(Suppl 1):10-5. PubMed ID: 26924590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Update on current care guidelines: benign prostatic hyperplasia].
    Tammela T; Nurmi M; Pétas A; Sipilä R; Taari K
    Duodecim; 2012; 128(10):1046-7. PubMed ID: 22724320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.